Q32 Bio (QTTB) EBIT (QoQ) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Q32 Bio | 162.94 Mn | 112.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -116.83% |
| Dec 31, 2025 | 705.50% |
| Sep 30, 2025 | 17.38% |
| Jun 30, 2025 | 25.00% |
| Mar 31, 2025 | 15.82% |
| Dec 31, 2024 | 22.79% |
| Sep 30, 2024 | -4.99% |
| Jun 30, 2024 | -20.72% |
| Mar 31, 2024 | 42.49% |
| Dec 31, 2023 | -230.97% |
| Sep 30, 2023 | -7.19% |
| Jun 30, 2023 | 1.33% |
| Mar 31, 2023 | -107.53% |
| Dec 31, 2022 | 397.87% |
| Sep 30, 2022 | -16.09% |
| Jun 30, 2022 | 24.75% |
| Mar 31, 2022 | -189.11% |
| Dec 31, 2021 | 237.68% |
| Sep 30, 2021 | -0.36% |
| Jun 30, 2021 | -2,649.95% |
| Mar 31, 2021 | 96.27% |
| Dec 31, 2020 | -5.41% |
| Sep 30, 2020 | 20.80% |
| Jun 30, 2020 | 2.18% |
| Mar 31, 2020 | -42.78% |
| Dec 31, 2019 | 18.31% |
| Sep 30, 2019 | -11.85% |
| Jun 30, 2019 | -11.34% |
| Mar 31, 2019 | -24.54% |
| Dec 31, 2018 | -29.02% |
| Sep 30, 2018 | -16.49% |
| Jun 30, 2018 | -25.49% |
| Mar 31, 2018 | 12.77% |
| Dec 31, 2017 | -83.99% |
| Sep 30, 2017 | -10.37% |
| Jun 30, 2017 | -28.71% |